Skip to main content
. 2022 May 17;12:178. doi: 10.1038/s41398-022-01943-9

Fig. 3. Intra-mPFC infusion of IGF-1 nAb at 2-h post-ketamine blocks the antidepressant-like effects of ketamine.

Fig. 3

a Experimental timeline for behavioral testing after i.p. injection of either saline or ketamine (10 mg/kg) and intra-mPFC infusion of either control IgG (160 ng/side) or IGF-1 nAb (160 ng/side). b Immobility time in the forced swim test (FST) 1 day after i.p. and intra-mPFC injections (interaction, F1,25 = 5.24, p = 0.0308, n = 6–8). c Locomotor activity (LMA) 2 days after i.p. and intra-mPFC injections (interaction, F1,25 = 1.22, p = 0.279, n = 6–8). d Time spent sniffing female urine in the female urine sniffing test (FUST) 3 days after i.p. and intra-mPFC injections (interaction, F1,25 = 8.59, p = 0.0071, n = 6–8). e Latency to feed in the novelty-suppressed feeding (NSF) test 4 days after i.p. and intra-mPFC injections (interaction, F1,25 = 6.81, p = 0.0151, n = 6–8). f Home cage feeding (HCF) just after the NSF (interaction, F1,25 = 0.356, p = 0.556, n = 6–8). g Schematic representation of mPFC infusion sites. Plates are from ref. [50]; 1.94, 1.78, 1.70, and 1.54 indicate distances (mm) from bregma. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by Holm–Sidak’s post hoc test).